Search
Encorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigational[L3344] On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic … Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.
Xanthinol
go.drugbank.com/drugs/DB09092ApprovedWithdrawn[L1079] Xaninthol is known to be a potent vasodilator that can easily pass through the cell membrane and once inside the cell it causes an increase in glucose metabolism resulting in an increased energy … [L1080] It was approved as a drug in 1998 in Canada and nowadays its status is cancelled post marketing.
Luliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalIt was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan. … Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes.
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseOxyphenonium
go.drugbank.com/drugs/DB00219ApprovedIt is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect. [PubChem] … A quaternary ammonium anticholinergic agent with peripheral side effects similar to those of atropine.
Categories: Drugs for Functional Gastrointestinal DisordersSynonyms: Oxyphenonium ionAcetyl sulfisoxazole
go.drugbank.com/drugs/DB14033ApprovedVet approvedSulfisoxazole acetyl competes with PABA for the bacterial enzyme, _dihydropteroate synthase_, preventing the incorporation of PABA into dihydrofolic acid, which is the precursor of folic acid. … It is often combined with erythromycin to treat acute otitis media caused by the bacteria, haemophilus influenzae [L2790].
Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells
go.drugbank.com/drugs/DB15731InvestigationalEnrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured tissue. … feature allows them to be hypoimmunogenic and non-inducible for tumorigenesis.
Anacaulase
go.drugbank.com/drugs/DB17449ApprovedInvestigational[L44717] Anacaulase is indicated for eschar removal in patients with deep partial thickness and/or full-thickness thermal burns. … and the N-linked glycan of stem bromelain and small molecule metabolites.
Human papillomavirus type 31 L1 capsid protein antigen
go.drugbank.com/drugs/DB10310ApprovedInvestigationalHuman papillomavirus type 31 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 31.
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTION, GARDASİL 9 IM ENJEKSİYONLUK SÜSPANSİYON, 1 ADET ŞIRINGA+2 ADET İĞNENorgestimate
go.drugbank.com/drugs/DB00957ApprovedInvestigationalNorgestimate was first described in the literature in 1977. … [A191068] It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat moderate acne vulgaris.
Synonyms: (17α)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime, (+)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one oxime acetate (ester)Mixtures: TriNessa Lo, TriNessa LoImatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalBrian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy". … [L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]